8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


                               September 13, 2005

                Date of Report (Date of earliest event reported)


                                 ORAGENICS, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


           Florida                    000-50614                   59-3410522
- ----------------------------        -------------            -------------------
(State or other jurisdiction         (Commission                (IRS Employer
      of incorporation)              File Number)            Identification No.)


                            13200 Progress Boulevard
                             Alachua, Florida 32615
           -----------------------------------------------------------
           (Address of principal executive offices including zip code)


                                 (386) 418-4018
               ---------------------------------------------------
               Registrant's telephone number, including area code


- --------------------------------------------------------------------------------
                                      None
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)
- --------------------------------------------------------------------------------


================================================================================



Item 5.02  Departure of Director or Principal Officers; Election of Directors;
           Appointment of Principal Officers

      On September 9, 2005, Dr. Robert T. Zahradnik was named president and
chief executive officer of the Company discontinuing his status as acting
president and chief executive officer. The employment arrangement with Dr.
Zahradnik otherwise has not changed whereby he will be compensated $15,000 per
month and will receive medical and dental insurance and retirement compensation
consistent with the Company benefits offered to all employees.

      A copy of the September 13, 2005 press release announcing the permanent
appointment of Dr. Zahradnik as chief executive officer and president is
attached to this report as Exhibit 99.1 and is incorporated herein by reference.


Item 9.01  Financial Information and Exhibits

           -------------------- ------------------------------------------
           Exhibit No.          Description
           -------------------- ------------------------------------------
           99.1                 Press Release dated September 13, 2005
           -------------------- ------------------------------------------





                                   SIGNATURES

      In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized on this 13th day of September, 2005.


                               ORAGENICS, INC.
                               (Registrant)

                               BY:     /s/ Robert T. Zahradnik
                                       -------------------------------------
                                       Robert T. Zahradnik
                                       President and Chief Executive Officer

EX-99.1

                                                                    Exhibit 99.1


Oragenics Names Robert Zahradnik as President, CEO

ALACHUA, FL. - September 13, 2005--Oragenics, Inc. (AMEX:ONI ) today announced
that Robert Zahradnik has been named President, Chief Executive Officer. Dr.
Zahradnik had been the Acting President, Chief Executive Officer since July,
2005 when he replaced Mento A. Soponis, who had retired from the post.

Dr. Zahradnik, a co-founder of Oragenics, was a member of the company's Board of
Directors from November 1996 until July, 2005, when he resigned his Board seat
so that the Company could remain in compliance with SEC rules regarding the mix
of independent and inside directors. Prior to joining Oragenics as an employee
in July, Dr. Zahradnik spent his career with Johnson & Johnson (NYSE: JNJ) in
various R&D management positions, with Advanced Clinical Technologies as
chairman and CEO, and as partner and general manager at Pro-Dentec Therapeutics.

"At Oragenics, Dr. Zahradnik has continued to utilize his extensive experience
in strategic planning and project management to position the Company to meet its
short and long-term objectives and to build shareholder value," commented David
Gury, Chairman of the Board.

Paul Hassie, Oragenics Chief Financial Officer, added, "Dr. Zahradnik has shown
in his career that he understands the importance of building the strengths of an
organization. With Bob and our current senior staff, we believe we have a strong
Management team in place and are confident of continued progress."

Oragenics is focused on the acquisition and development of novel technologies
and products to address significant, unmet medical needs.

Oragenics' strategy is to license and develop products through human
proof-of-concept studies prior to partnering with major pharmaceutical,
biotechnology or healthcare product firms for advanced clinical development and
commercialization.

Oragenics is currently developing several products, which address potentially
major market opportunities as follows:

      o     SMaRT Replacement Therapy is a single, painless topical treatment
            that has the potential to offer life-long protection from most tooth
            decay. This product is in Phase I clinical trials.

      o     Probiora 3 Oral Probiotic is a daily consumer product that employs
            naturally occurring beneficial bacteria to promote dental and
            periodontal health.

      o     MU 1140 is a novel antibiotic with activity against essentially all
            Gram-positive bacteria including multidrug resistant Staphylococcus
            aureus and Enterococcus faecalis. MU 1140 has a number of other
            characteristics that suggest its potential use in the treatment of a
            variety of infectious diseases.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements that reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect," "anticipate,"
"intend," "estimate," "project" and similar expressions that do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to (1)
the ability to successfully complete development and commercialization of
Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic,
and probiotic product for oral health; (2) the ability to obtain substantial
additional funding; (3) the ability to develop and commercialize products before
competitors; (4) the ability to develop commercial products with the in-licensed
technology; and (5) other factors detailed from time to time in filings with the
Securities and Exchange Commission. We expressly disclaim any responsibility to
update forward-looking statements.


- -----------------------
Contact:
     Oragenics, Inc.
     Paul A. Hassie, 386-418-4018 X232
     www.oragenics.com
     -----------------
     or
     Investor Awareness, Inc.
     Tony Schor, 847-945-2222
     www.investorawareness.com
     -------------------------